Axel Schörling

Executive

Chief Executive Officer

Insider activity · 24 months2 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 1 buy · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 1 buy · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 1 saleApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (1 ops.)

€28k

▼ Sales (1 ops.)

€113k

Latest filing published 27 Mar 2026 for EQL Pharma AB, €113k. Read the official filing

Filing timeline

BuySale

Axel Schörling

Insider track record

Disclosed buys

Disclosed sells

T+90 hit rate

50%

T+90 mean return

-17.4%

Across 2 buy signals with a settled T+90 return. Return basis: close on the day after publication.

Signal history

Axel Schörling: trading record in brief

This profile gathers the share dealings of Axel Schörling in EQL Pharma AB, where the filings describe the role as chief executive. Between 16 May 2025 and 27 March 2026, the trades on record add up to 4 filings.

Both buying and selling appear: 1 purchase worth €28k, against 1 sale worth €113k. Sales outweigh purchases by €86k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. 2026 to date brings no purchases and 1 sale.

The latest filing, published on 27 March 2026, reports an open-market sale of €113k in EQL Pharma AB. The clock since the last published purchase (16 May 2025) now reads 520 days. Most trades are made public on the day they happen. For comparison, MAR article 19 gives managers three business days to notify a trade. Every figure here comes from the filings published by Finansinspektionen and describes the past, not future prices; it is not investment advice.